Interleukin Raises $3M in Private Placement | GenomeWeb

NEW YORK (GenomeWeb News) – Interleukin Genetics today said it has completed a private placement with Delta Dental Plan of Michigan, resulting in an investment of $3 million.

The investment consists of 500,000 shares of Interleukin Series B convertible preferred stock. Each share is convertible into about 21.86 shares of common stock reflecting a conversion price of $.2745 per share. Delta also obtains one seat on Interleukin's board immediately, replacing one of the Series A directors.

BTIG acted as the exclusive placement agent on the placement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.